Latest Animal Health News

Page 2 of 6
Vitrafy Life Sciences has delivered key milestones in the first half of FY26, including a strategic partnership with IMV Technologies and progress in clinical studies, while maintaining a strong cash position to support its U.S. expansion and product launches.
Ada Torres
Ada Torres
4 Feb 2026
Apiam Animal Health shareholders have overwhelmingly approved the proposed acquisition by Adamantem Capital-controlled entities, clearing a critical hurdle for the $500 million deal.
Ada Torres
Ada Torres
3 Feb 2026
Apiam Animal Health shareholders convened on 3 February 2026 to vote on a scheme of arrangement proposing acquisition by Adamantem Capital Fund II, with the board unanimously recommending approval. The scheme offers $0.87 cash per share or scrip alternatives, pending final court approval.
Ada Torres
Ada Torres
3 Feb 2026
Apiam Animal Health shareholders have predominantly elected to receive scrip or mixed consideration in the proposed acquisition, with a special dividend of 10 cents per share proposed pending scheme approval.
Ada Torres
Ada Torres
2 Feb 2026
Invion Limited has secured a $2 million non-dilutive grant from the South Korean government to advance preclinical studies for oesophageal cancer, expanded its global Photosoft technology license, and raised $1.3 million via convertible notes to strengthen its financial position.
Ada Torres
Ada Torres
30 Jan 2026
Terragen Holdings reports a strong quarter with an 87% increase in sales of its ruminant probiotic and advances key livestock and crop trials, positioning itself for expanded market access.
Ada Torres
Ada Torres
30 Jan 2026
Paradigm Biopharmaceuticals reports solid progress in its Phase 3 knee osteoarthritis trial, expanding internationally and publishing key Phase 2 biomarker data. The company maintains a robust cash position to support ongoing clinical milestones.
Ada Torres
Ada Torres
30 Jan 2026
Neurizon Therapeutics has cleared a major regulatory hurdle with the FDA lifting the clinical hold on its lead drug NUZ-001 and secured a comprehensive $33 million funding package to advance its pivotal ALS trial.
Ada Torres
Ada Torres
30 Jan 2026
Vitrafy Life Sciences has marked significant progress in Q2 FY2026 with a strategic partnership, commercial launch in North America, and advancing clinical trials, underpinning its growth in cryopreservation technology.
Ada Torres
Ada Torres
29 Jan 2026
Apiam Animal Health has secured Foreign Investment Review Board approval for its acquisition by Adamantem Capital, paving the way for a crucial shareholder vote in February.
Ada Torres
Ada Torres
12 Jan 2026
Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.
Ada Torres
Ada Torres
23 Dec 2025
Apiam Animal Health Limited shareholders are set to vote on a scheme of arrangement offering $0.87 cash per share or a mix of cash and unlisted scrip in a new holding company controlled by Adamantem Capital. The Independent Expert deems the cash offer fair and reasonable, while scrip options carry liquidity and minority risks.
Ada Torres
Ada Torres
12 Dec 2025